Information  X 
Enter a valid email address

Company Name matching 'Sanofi'

Date
Time Source
Company
Announcement
23 Nov 2020 9:00 am GNW   Sanofi European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
18 Nov 2020 6:12 pm GNW   Sanofi European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
  6:15 am GNW   Sanofi Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
  6:00 am GNW   Sanofi FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
14 Nov 2020 12:00 am GNW   Sanofi FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
02 Nov 2020 6:15 am GNW   Sanofi Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
29 Oct 2020 1:50 pm GNW   Sanofi European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
  6:30 am GNW   Sanofi Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER
  6:00 am GNW   Sanofi Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
28 Oct 2020 6:00 am GNW   Sanofi Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
26 Oct 2020 12:00 pm GNW   Sanofi Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
16 Oct 2020 1:00 pm GNW   Sanofi CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15 Oct 2020 1:00 pm GNW   Sanofi Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
13 Oct 2020 6:00 am GNW   Sanofi Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
02 Oct 2020 6:00 am GNW   Sanofi EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
28 Sep 2020 2:30 pm GNW   Sanofi Sanofi completes Principia Biopharma Inc. acquisition
25 Sep 2020 6:30 am GNW   Sanofi Availability of the Q3 2020 Memorandum for modelling purposes
22 Sep 2020 5:30 pm GNW   Sanofi Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
  6:00 am GNW   Sanofi Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.
21 Sep 2020 1:25 pm GNW   Sanofi Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
  1:25 am GNW   Sanofi Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
18 Sep 2020 8:05 am GNW   Sanofi Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 
  6:00 am GNW   Sanofi Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
14 Sep 2020 6:00 am GNW   Sanofi FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
10 Sep 2020 6:00 am GNW   Sanofi New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
08 Sep 2020 6:00 am GNW   Sanofi Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
03 Sep 2020 6:00 am GNW   Sanofi Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
01 Sep 2020 6:00 am GNW   Sanofi Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
28 Aug 2020 6:00 am GNW   Sanofi Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
17 Aug 2020 6:00 am GNW   Sanofi Sanofi to acquire Principia Biopharma
31 Jul 2020 8:20 pm GNW   Sanofi Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
  12:00 pm GNW   Sanofi Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
30 Jul 2020 7:15 am GNW   Sanofi Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial
29 Jul 2020 4:29 pm GNW   Sanofi Online availability of Sanofi’s half-year financial report for 2020
  6:30 am GNW   Sanofi Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
  6:00 am GNW   Sanofi Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
06 Jul 2020 9:30 pm GNW   Sanofi Availability of the Pre-quarterly Results Communication
02 Jul 2020 9:30 pm GNW   Sanofi Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
23 Jun 2020 6:00 am GNW   Sanofi Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients
  5:59 am GNW   Sanofi Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
19 Jun 2020 2:00 pm GNW   Sanofi Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors 
  12:30 pm GNW   Sanofi Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
16 Jun 2020 1:00 pm GNW   Sanofi Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease
  11:00 am GNW   Sanofi Sanofi invests to make France its world class center of excellence in vaccine research and production
11 Jun 2020 6:00 am GNW   Sanofi Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases
08 Jun 2020 6:00 am GNW   Sanofi Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease
03 Jun 2020 5:00 pm GNW   Sanofi Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan
02 Jun 2020 2:00 pm GNW   Sanofi Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
  11:47 am GNW   Sanofi European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma
  6:00 am GNW   Sanofi Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline
29 May 2020 9:01 pm GNW   Sanofi Sanofi announces closing of Regeneron stock sale
  1:00 pm GNW   Sanofi Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
  6:00 am GNW   Sanofi Sanofi names new leaders to Executive Committee
28 May 2020 5:05 pm GNW   Sanofi Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director
27 May 2020 12:55 am GNW   Sanofi Sanofi announces pricing of Regeneron stock offering
26 May 2020 4:40 pm GNW   Sanofi Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
25 May 2020 5:45 pm GNW   Sanofi Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
22 May 2020 11:25 pm GNW   Sanofi Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
18 May 2020 6:00 am GNW   Sanofi Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event
14 May 2020 6:00 am GNW   Sanofi FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t